Revolutionise care for people and planet

New white paper calls for integration of environmental, human and economic metrics in sustainability assessments of medical technologies.

Mölnlycke Health Care, a world leading MedTech company, has expanded its commitment to operations in the Middle East by extending its stake from 33.3% to 60% to become majority shareholder in Tamer Mölnlycke Care - a joint venture with Tamer Group, the market leader in healthcare distribution in the Kingdom of Saudi Arabia.

Mölnlycke intends to issue a new 10-year EUR bond and launches a tender offer for the outstanding EUR 500m bond due February 2025.

On 28 April 2023, Mölnlycke entered into a new EUR 350 million multicurrency revolving credit facility. The facility has a tenor of five years with two one-year extension options and will be used as a backup for general corporate purposes. The facility is a refinancing of the existing and undrawn revolving credit facility signed in 2017.

Mölnlycke signed an agreement to acquire P.G.F. Industry Solutions GmbH, the manufacturer of Granudacyn®, a range of solutions for wound cleansing and moisturizing.

Mölnlycke Health Care is pleased to announce our partnership with Phoenix Society for Burn Survivors.

The world’s largest and most trusted provider of business sustainability ratings - EcoVadis, has awarded Mölnlycke a gold medal for our focus on sustainability. They have ranked us in the top 3% of companies worldwide.

Today we are delighted to announce the launch of the Mölnlycke integrated Annual Report 2023. Our dedication to revolutionising care for people and planet contributed to a very successful year with record high annual net sales of EUR 1,924 million and substantial improvements in profitability. We continue to report our sustainability achievements in accordance with the Global Reporting Initiative (GRI) standards.